CA2074641A1 - Method of treating ocular inflammation - Google Patents

Method of treating ocular inflammation

Info

Publication number
CA2074641A1
CA2074641A1 CA2074641A CA2074641A CA2074641A1 CA 2074641 A1 CA2074641 A1 CA 2074641A1 CA 2074641 A CA2074641 A CA 2074641A CA 2074641 A CA2074641 A CA 2074641A CA 2074641 A1 CA2074641 A1 CA 2074641A1
Authority
CA
Canada
Prior art keywords
ocular inflammation
treating ocular
mammal
treating
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2074641A
Other languages
French (fr)
Other versions
CA2074641C (en
Inventor
Prasad Shrikrishna Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
Prasad Shrikrishna Kulkarni
University Of Louisville Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prasad Shrikrishna Kulkarni, University Of Louisville Research Foundation, Inc. filed Critical Prasad Shrikrishna Kulkarni
Publication of CA2074641A1 publication Critical patent/CA2074641A1/en
Application granted granted Critical
Publication of CA2074641C publication Critical patent/CA2074641C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is a method and composition for treating ocular inflammation in a mammal in need of such treatment, including administering to the mammal an anti-inflammatory amount of rapamycin. <IMAGE>
CA002074641A 1991-07-25 1992-07-24 Method of treating ocular inflammation Expired - Lifetime CA2074641C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73560491A 1991-07-25 1991-07-25
US735,604 1991-07-25

Publications (2)

Publication Number Publication Date
CA2074641A1 true CA2074641A1 (en) 1993-01-26
CA2074641C CA2074641C (en) 1999-05-04

Family

ID=24956475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002074641A Expired - Lifetime CA2074641C (en) 1991-07-25 1992-07-24 Method of treating ocular inflammation

Country Status (20)

Country Link
US (1) US5387589A (en)
EP (1) EP0532862B1 (en)
JP (1) JP2568962B2 (en)
KR (1) KR100216768B1 (en)
AT (1) ATE133336T1 (en)
AU (1) AU653415B2 (en)
CA (1) CA2074641C (en)
CZ (1) CZ285660B6 (en)
DE (1) DE69207847T2 (en)
DK (1) DK0532862T3 (en)
ES (1) ES2083030T3 (en)
HK (1) HK1005705A1 (en)
HU (1) HU211218B (en)
IE (1) IE922430A1 (en)
IL (1) IL102414A (en)
MX (1) MX9204381A (en)
NZ (1) NZ243679A (en)
RU (1) RU2048812C1 (en)
SK (1) SK280511B6 (en)
ZA (1) ZA924953B (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3158437B2 (en) * 1991-04-26 2001-04-23 藤沢薬品工業株式会社 Use of macrolide compounds for eye diseases
CH686761A5 (en) * 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
AT408520B (en) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Pharmaceutical formulations
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (en) * 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
JPH09278653A (en) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd Retinal disease-treating preparation
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
KR19990048077A (en) * 1997-12-08 1999-07-05 전원중 Manufacturing method of artificial marble molding
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
CA2306393C (en) * 1998-07-14 2008-12-23 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
NZ513111A (en) * 1998-12-24 2003-10-31 R Tech Ueno Ltd Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ES2313983T3 (en) 2000-09-19 2009-03-16 Wyeth RAPAMYCIN HYDROSOLUBLE ESTERS.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
ATE305932T1 (en) 2001-08-22 2005-10-15 Wyeth Corp RAPANYCIN29-ENOLE
HUP0500698A2 (en) * 2001-11-19 2006-08-28 Novartis Ag Use of an ascomycin for the treatment of blepharitis
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
JP4265888B2 (en) * 2002-06-12 2009-05-20 株式会社リコー Image forming apparatus
DK1553940T3 (en) 2002-07-30 2008-06-02 Wyeth Corp Patent formulations containing a rapamycin hydroxyester
BR0314397A (en) * 2002-09-17 2005-08-09 Wyeth Corp Oral Formulations
DK1539157T3 (en) 2002-09-18 2013-10-07 Univ Pennsylvania METHOD OF INHALING CHOROIDAL NEOVASCULARIZATION
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042938A1 (en) * 2003-02-06 2005-07-06 Wyeth Corp USE OF CCI-779 IN THE TREATMENT OF HEPATIC FIBROSIS
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
DK1615640T3 (en) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastic Compositions
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (en) * 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. LIQUID FORMULATION
BRPI0609432A2 (en) * 2005-03-21 2010-04-06 Macusight Inc drug delivery systems for treating diseases or conditions
EP1890652B1 (en) 2005-05-13 2017-08-02 Akkolens International B.V. Intra-ocular artificial lens for iris-driven accommodation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
PL1904056T3 (en) 2005-07-18 2009-09-30 Minu Llc Use of a macrolide to restore corneal sensation
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (en) * 2006-03-23 2014-05-28 参天製薬株式会社 Formulations and methods for diseases or conditions associated with vascular permeability
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2083834B1 (en) 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN101918019B (en) 2007-10-08 2014-11-26 奥里尼亚制药有限公司 Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
KR20100090278A (en) * 2007-11-27 2010-08-13 알콘 리서치, 리미티드 Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
KR20110074758A (en) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 Macrocyclic lactone compounds and methods for their use
CN102612564B (en) 2009-04-10 2015-08-26 齐海燕 New anti-ageing reagent and discrimination method thereof
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
CA2972296A1 (en) 2016-06-30 2017-12-30 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
WO2018148508A1 (en) 2017-02-10 2018-08-16 Mount Tam Biotechnologies, Inc. Rapamycin analog
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR102619458B1 (en) 2017-06-16 2023-12-29 학교법인 도시샤 Medicines and applications thereof for treating or preventing ocular symptoms, disorders or diseases, including mTOR inhibitors
TW202135806A (en) 2019-12-26 2021-10-01 日商參天製藥股份有限公司 Aqueous suspension composition containing sirolimus or salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (en) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison PHARMACEUTICAL COMPOSITIONS BASED ON RAPAMYCIN FOR THE TREATMENT OF CARCINOGENIC TUMORS
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE69016515T2 (en) * 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Aqueous liquid agent for external use.

Also Published As

Publication number Publication date
EP0532862B1 (en) 1996-01-24
IL102414A0 (en) 1993-01-14
DK0532862T3 (en) 1996-02-19
IL102414A (en) 1996-08-04
US5387589A (en) 1995-02-07
KR930001913A (en) 1993-02-22
CA2074641C (en) 1999-05-04
JP2568962B2 (en) 1997-01-08
MX9204381A (en) 1993-02-01
ZA924953B (en) 1993-04-28
EP0532862A1 (en) 1993-03-24
ATE133336T1 (en) 1996-02-15
HK1005705A1 (en) 1999-01-22
DE69207847D1 (en) 1996-03-07
SK230792A3 (en) 1996-05-08
KR100216768B1 (en) 1999-09-01
AU653415B2 (en) 1994-09-29
SK280511B6 (en) 2000-03-13
RU2048812C1 (en) 1995-11-27
ES2083030T3 (en) 1996-04-01
DE69207847T2 (en) 1996-05-30
JPH05194212A (en) 1993-08-03
CZ230792A3 (en) 1993-02-17
HUT63763A (en) 1993-10-28
HU9202448D0 (en) 1992-10-28
AU2035092A (en) 1993-01-28
IE922430A1 (en) 1993-01-27
NZ243679A (en) 1997-06-24
HU211218B (en) 1995-11-28
CZ285660B6 (en) 1999-10-13

Similar Documents

Publication Publication Date Title
AU653415B2 (en) Method of treating ocular inflammation
AU2187992A (en) Composition and method for disease treatment
PT646012E (en) CURE OF WOUNDS AND TREATMENT OF FIBROTIC PERTURBACTIONS BY TGFBETA-3
AU5860396A (en) Substituted oxazoles for the treatment of inflammation
AU7807791A (en) Method of treating impotence
CA2090574A1 (en) Method of inhibiting nitric oxide formation
JPS56166114A (en) Antiinflammatory medicinal composition
EP0648121A1 (en) Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis.
CA2060208A1 (en) Wound healing
AU3066789A (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
AU8192691A (en) Method of treatment and compositions therefore
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
AU7770991A (en) Method and composition for the treatment of cancer
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
CA2061907A1 (en) Treatment of ocular hypertension with a synergistic combination
EP0618812A4 (en) Use of protease nexin-i as an antiinflammatory.
AU7719491A (en) Therapeutic compound
CA2188871A1 (en) Method for Treating Psoriasis
EP0260790A3 (en) Use of pinacidil in the treatment of incontinence
AU635045B2 (en) Agent for preventing and treating opacity of lens
AU5903690A (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence
UA10928C2 (en) Method for prevention of hypercholesterolemia
AU1515197A (en) Methods and compositions for treating infection using optically pure (S)-lomefloxacin
AU7078691A (en) Use of urapidile and derivatives for treating arteriosclerotic diseases
HK1111636A1 (en) Fluprostenol isopropyl ester for use in the treatment of glaucoma and ocular hypertension

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry